Evotec and Variant Bio Partner to Discover and Develop Fibrosis Treatments
The Hamburg headquartered publicly listed drug discovery and development company Evotec and Variant Bio, a US-based biotech company leveraging the
Read moreThe Hamburg headquartered publicly listed drug discovery and development company Evotec and Variant Bio, a US-based biotech company leveraging the
Read moreIn a proof-of-concept study, researchers at the National Institutes of Health (NIH) explored the feasibility of employing transfer learning, a machine
Read moreVentus Therapeutics, a US-based clinical-stage biopharmaceutical company leveraging its exclusive structural biology and computational chemistry platform, ReSOLVE™, has disclosed promising
Read morePreclinical data shows that Nutcracker’s mRNA drug candidate NTX-470 effectively targets CD3 T cells, demonstrating selective engagement with minimal unintended
Read moreVertex Pharmaceuticals Incorporated and Alpine Immune Sciences, Inc., a biotechnology firm dedicated to pioneering protein-based immunotherapies, jointly announced the signing
Read morePfizer has announced encouraging findings from its ongoing pivotal Phase 3 clinical trial, known as MONeT (RSV IMmunizatiON Study for
Read moreThe U.S. Food and Drug Administration has approved the use of cell therapies developed by Johnson & Johnson (JNJ.N) and Bristol Myers Squibb (BMY.N) for treating
Read moreThe US FDA has approved AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) as the first tumor-agnostic HER2-directed therapy for the
Read moreAstraZeneca has announced it is set to acquire Amolyt Pharma, a French clinical-stage biotechnology company focused on developing novel treatments
Read moreResearchers have made a significant leap forward in the fight against drug-resistant tuberculosis (TB), according to a recent study published in
Read more